With the robust demand for personalized medicines and the growing adoption of digital technology, the precision medicine ...

Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...

Q4 2024 Earnings Call Transcript February 20, 2025 Prothena Corporation plc misses on earnings expectations. Reported EPS is ...

The OCEANIC-AF trial has raised concerns about factor XI inhibitors. Should physicians still bet on this class of ...

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space ...

Sandra Leung began her legal career prosecuting homicides, a formative experience that she once said taught her "to make ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Up to 7% of patients with metastatic disease have dMMR or MSI-H tumours ... global programme lead, late development, oncology, BMS, said: “The benefit of dual inhibition of PD-1 and CTLA-4 has been ...

and discontinuation rates were 14.6% and 6.7%, respectively. The results nevertheless make Opdualag an alternative to Opdivo plus Yervoy (ipilimumab) – BMS' notoriously hard to tolerate CTLA4 ...

Under the contract Leonardo DRS will provide its ruggedized C4I Battle Management System (BMS) hardware and is the lead integrator for the technology. The work includes integrating BMS software, cyber ...

Ciltacabtagene autoleucel improved minimal residual disease negativity and sustained responses vs standard care in ...

February 20, 2025) - LiTime, a global leader in lithium iron phosphate (LFP) battery technology, has announced that its highly anticipated 2025 flagship product, the LiTime 12V 165Ah Bluetooth Lithium ...